Clinical course of patients treated for advanced ovarian carcinoma without surgical intervention.

OBJECTIVE: To describe the clinical course and outcome of patients with non-surgically-treated advanced ovarian cancer attending a single institute. METHODOLOGY/PRINCIPAL FINDINGS: We reviewed the medical charts of all patients with advanced epithelial ovarian cancer who underwent chemotherapy at a tertiary medical center between January 2005 and December 2010 but were never operated. Data on patient characteristics, disease course, and outcome were collected from patient files. Sixteen patients met the inclusion criteria. Eight (50%) were diagnosed with apparent FIGO stage IIIC disease, and 8 with stage IV. Five patients (31%) achieved a complete clinical response, and 11 (69%) achieved a partial response. Among the complete responders, the median disease-free interval was 8 months (range 7-11 months). In all of them, the disease recurred and second-line chemotherapy was administered. Of them, four (80%) achieved a second complete response. Partial responders had up to four lines of chemotherapy, with continued disease progression. The median overall survival of the whole group was 19.5 months, and of the complete responders, 28 months. CONCLUSIONS/SIGNIFICANCE: Most patients with advanced ovarian carcinoma who will not undergo surgery respond only partially to first-line chemotherapy. Having no surgery is associated with a short disease-free interval

First line chemotherapy for patients never treated surgically.

<p>First line chemotherapy for patients never treated surgically.</p

Patient characteristics at diagnosis of ovarian carcinoma.

<p>FIGO-International Federation of Gynecology and Obstetrics.</p

Patients with ovarian carcinoma treated without surgical intervention – flowchart of expected outcomes.

<p>Patients with ovarian carcinoma treated without surgical intervention – flowchart of expected outcomes.</p

A new computer-aided diagnostic tool for non-invasive characterisation of malignant ovarian masses: results of a multicentre validation study.

To prospectively assess an innovative computer-aided diagnostic technology that quantifies characteristic features of backscattered ultrasound and theoretically allows transvaginal sonography (TVS) to discriminate benign from malignant adnexal masses.Evaluation StudiesJournal ArticleMulticenter StudyValidation StudiesSCOPUS: ar.jinfo:eu-repo/semantics/publishe